Monthly information on share capital and company voting rights
May 06, 2024 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
May 06, 2024 08:00 ET
|
Pacific Software Inc.
Pacific Software acquires Dreamaderm assets, including Dermatrix, a peptide-enhancing cosmeceutical for diverse dermatological applications.
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
May 06, 2024 06:25 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power...
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
May 06, 2024 02:00 ET
|
Cellectis Inc.
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
May 02, 2024 17:00 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
May 02, 2024 16:30 ET
|
Cellectis Inc.
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024 16:10 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial
May 02, 2024 06:00 ET
|
Smart Immune
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial PARIS, France, May 2, 2024 – Smart Immune, a clinical-stage biotechnology company developing...
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
May 01, 2024 08:05 ET
|
Tevogen Bio Inc
For full year 2023, the operating expenses for Tevogen Bio Inc were $8.8 million.
New YPrime Report Highlights eCOA's Impact on CNS Trials
May 01, 2024 08:00 ET
|
Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.